Industry Today - Market Research Reports and PR distribution’s Post

#Tagraxofusp: the first #CD123-targetedagent in oncology and the first grug specifically approved for #blasticplasmacytoiddendriticcellneoplasm. Read the new review on its development, key preclinical insights, clinical data, and its unique toxicity, the capillary leak syndrome. https://lnkd.in/dsjNx6X3

Imaging plays a critical role in assessing drug efficacy in #clinicaltrials. However, variability in imaging interpretation can lead to discrepancies in the trial results, which can have significant implications.   In this webinar you’ll hear from pharmacology researchers and oncology medical experts as they explore challenges of site versus central image reading in #oncology clinical trials. Learn more about factors that can contribute to discrepancies, including real-world examples, and ways we can address and overcome those challenges.   Watch the recording below 👇 or click here: https://lnkd.in/eqsZg6gr   #MedianWebinar #drugdevelopment #oncologytrials #medicalimaging

FDA Oncology medical reviewers wrote more than 500 articles for peer-reviewed journals from 2018-2023 #CancerTreatment #ClinicalTrialData #DrugApproval #FDAOncology #Healthcare #MedicalResearch #OncoDaily #Oncology

With over 25 years of experience in research, technology, and biotech, Noelle Gaskill of Mirati Therapeutics approaches the challenges of DCTs with a comprehensive perspective, prioritizing listening to research sites. Get a sneak peek into her #ACRP2024 session, where she shares tactical insights from collaborating with thought-leaders, regulators, and sites, aiming to launch a hybrid DCT interventional oncology trial this year. Learn more about Noelle's session in Anaheim > https://bit.ly/3T5ahLX #GoForIt #GoForEducation #ClinicalTrials #ClinicalResearch #ClinicalTrialDesign #DCT #DecentralizedClinicalTrials

Pulse 2.0 interviewed Partha Ray, MD, OT/3NDx Founder and Chairman, to get an update on the company and plans for expanded commercialization. Check out the full interview at https://bit.ly/4cFs596 where Dr. Ray discusses his motivation to start the company, how he assembled a management dream team, the significant impact VERESCA will have for oncology patients, physicians, payers and pharma, and how the company plans to accelerate growth. #Onconostic @Pulse2news #VERESCA #oncology

Sumit Verma is our next speaker, presenting on the commercializing of Autologous Cell Therpies. This presentation focuses on the overall cell therapy market landscape, key learnings from unique CMC matters to scaling-up personalized therapies and to what regulators are expecting from late-stage oncology companies to receive expedited approvals. #ISPE #ISPEEA24 #ISPEEuropeAnnual

Ratio’s fully integrated proprietary R&D platforms, Trillium™ and Macropa™, harness the tumor-killing power of the alpha emitting radionuclide actinium-225 to selectively destroy #cancer cells. Ratio’s Trillium™ technology is a proprietary and innovative platform that modulates drug pharmacokinetics (PK) and improves drug availability, tumor delivery, and tumor loading, while simultaneously reducing the side effects commonly observed with other radiotherapies. Learn more: https://lnkd.in/e--KTJiH #radiopharmaceuticals #theranostics

Imaging plays a critical role in assessing drug efficacy in #clinicaltrials. However, variability in imaging interpretation can lead to discrepancies in the trial results, which can have significant implications.   In this webinar you’ll hear from pharmacology researchers and oncology medical experts as they explore challenges of site versus central image reading in #oncology clinical trials. Learn more about factors that can contribute to discrepancies, including real-world examples, and ways we can address and overcome those challenges.   Tune in to our on-demand webinar here: https://lnkd.in/ef7ycuJM #MedianWebinar #drugtrial 

What are the key regulatory topics for drug development in 2024? Patrick Brady, PharmD, Global Head, Therapeutic Innovation & Regulatory Science, shares the five noteworthy regulatory topics to closely monitor in 2024, including: - Master protocols in clinical trial design. - Patient outcomes in oncology. - Advancements of new modalities. - Use of AI/ML and digitizing clinical trials. Stay informed by reading the article: https://bit.ly/3ZGw4yu #DrugDevelopment #Oncology #AI #RegulatoryStrategy

OncoC4, Inc. Reports the First Patient Dosing in P-I Study of ONC-841 for Solid Tumors #oncoc4 #onc841 #solidtumors #clinicaltrial #firstpatientdosing #phase1 #monoclonalantibody #phagocytosis